DPLG3 

DPLG3 is a specific chymotryptic-like β5i subunits inhibitor, with an IC₅₀ of 4.5 nM. DPLG3 inhibits mouse i-20S with IC₅₀ of 9.4 nM. DPLG3 downregulates the protein levels of NF-κB p50 and p65. DPLG3 can be used for immune disease research^[1][2][3].

DPLG3 (1-5 μM, 2 h) downregulates the protein levels of NF-κB p50 and p65 in BMDMs cells isolated from tibia and femur of 6-8 weeks old C57BL/6 mice^[1].
DPLG3 (0.5-5 μM) suppresses T-cell proliferation in a concentration-dependent manner^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

DPLG3 (2.5-5 mg/kg, i.p., daily, starts on day 0 until day 12) attenuates disease progression in DSS-induced experimental colitis mice^[1].
DPLG3 (25 mg/kg, i.p., per day, 14 d) induces prolongation of heart allograft survival in mice (transplants BALB/c mice hearts into fully allogeneic C57BL/6 mice recipients)^[2].
DPLG3 (25 mg/kg) shows reduced CD4⁺ and CD8⁺ effector T cells in RAG^-/- C57BL/6 mice transferred into CD3⁺ CD25^- T cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

640.74

C₃₇H₄₁FN₄O₅

1801379-22-5

Solid

White to off-white

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

• [1]. Moallemian R, et al. Immunoproteasome inhibitor DPLG3 attenuates experimental colitis by restraining NF-κB activation. Biochem Pharmacol. 2020 Jul;177:113964.  [Content Brief]

  [2]. Sula Karreci E, et al. Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance in mice. Proc Natl Acad Sci U S A. 2016 Dec 27;113(52):E8425-E8432.  [Content Brief]

  [3]. Basler M, et al. On the role of the immunoproteasome in transplant rejection. Immunogenetics. 2019 Mar;71(3):263-271.  [Content Brief]